Banner - About IDA- Detecting and diagnosing IDA

Treating and Managing IDA

Overall, the treatment of IDA consists of remedying the underlying etiology and replenishing iron stores.25

IDA treatment goals26

  • Correct the anemia
  • Prevent a further fall in hemoglobin (Hb)
  • Avoid the use of blood transfusions
  • Increase Hb, serum ferritin, and transferrin saturation (TSAT) above the lower threshold of normal

IDA requires ongoing care to ensure iron levels stay where they need to be. Until a patient's iron returns to a sufficient level, which can take time depending on which therapy they are on, they may still experience symptoms like fatigue.

IDA requires ongoing care to ensure iron levels stay where they need to be. Until a patient's iron returns to a sufficient level, which can take time depending on which therapy they are on, they may still experience symptoms like fatigue.

Two common treatment options are oral and intravenous iron.1

IDA management and treatment options

There's more to evaluating IDA than hemoglobin levels

Patients with IDA may fail oral iron for a number of reasons

Patients with IDA may fail oral iron for a number of reasons

Oral iron is poorly absorbed, even in healthy patients27

Oral Iron Therapy Issues Icon

*Less than 10% absorption of oral iron is based on a regimen of 300-mg or 320-mg tablets 3 to 4 times a day.

Oral Iron Therapy Issues Icon Oral Iron Therapy Issues Icon

DID YOU KNOW? A wide variety of inflammatory conditions can elevate hepcidin, hindering oral iron absorption and reducing serum iron levels.28

Adherence issues

Oral Iron Therapy Adherence Rate Icon

Data show the adherence rate for oral iron therapy is 40%-60%.29
Adherence may be affected by side effects.27

Side effects

Oral Iron Therapy Side Effects Icon

10%-40% of patients taking oral iron may experience side effects, which could necessitate reduction of dose or dosing frequency.30

Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).24

Consider testing your patients 14 to 30 days after starting oral iron to see if they are having an adequate response to oral iron therapy31,32

Consider testing your patients 14 to 30 days after starting oral iron to see if they are having an adequate response to oral iron therapy31,32

100% of IV iron is delivered into the patient's bloodstream

100% of Injectafer iron is delivered into the patient’s bloodstream

If your patients do not respond adequately to oral iron,
you may want to consider IV iron

IV Iron Therapy Delivers 100% Iron Into Bloodstream

  • The full dose of IV iron is available to be utilized in hemoglobin production or stored as ferritin for future use as hemoglobin is depleted.33

Routinely test across all 3 key indices
to determine if your patient’s iron therapy is working34,35

When oral iron fails, it may be time to consider an IV iron like Injectafer

When oral iron fails, it may be time to consider an IV iron like Injectafer

CHOOSING INJECTAFER

CHOOSING INJECTAFER

Important Safety Information

INDICATIONS

Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.

WARNINGS AND PRECAUTIONS

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.

In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.

In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.

ADVERSE REACTIONS

In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).

The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.

To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see Full Prescribing Information.

References - About IDA